FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer By Ogkologos - September 19, 2025 508 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Cohort 2 of SunRISe-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Oral Cancer Taught Me How Much Words Matter April 21, 2021 For Early-Stage Lung Cancer, Study Identifies Potential New Biomarker, Treatment Target January 3, 2019 New Research in Treating Non-Small Cell Lung Cancer: 2022 North America... December 1, 2022 The Best And Worst Face Masks For COVID-19, Plus Face Masks... August 19, 2020 Load more HOT NEWS Targeted Radiation Reduces Pain from Cancer Metastases in the Spine Evaluation of Pemigatinib Efficacy in FGFR-Altered Advanced Solid Tumours Led to... Survey results reveal attitudes towards cancer screening during the pandemic 5 Tips for Managing Financial Stress During Cancer
